A Commentary on "Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis" (Int J Surg 2022;104:106767)
机构:[1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China [2]Department of VIP Medical Services & Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China [3]Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China 河北医科大学第四医院胸部放疗一病区临床科室[4]Department of VIP Medical Services & Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
第一作者机构:[1]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
通讯作者:
推荐引用方式(GB/T 7714):
Liu Yunsong,Men Yu,Wang Jun,et al.A Commentary on "Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis" (Int J Surg 2022;104:106767)[J].INTERNATIONAL JOURNAL OF SURGERY.2022,106:doi:10.1016/j.ijsu.2022.106929.
APA:
Liu Yunsong,Men Yu,Wang Jun&Hui Zhouguang.(2022).A Commentary on "Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis" (Int J Surg 2022;104:106767).INTERNATIONAL JOURNAL OF SURGERY,106,
MLA:
Liu Yunsong,et al."A Commentary on "Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis" (Int J Surg 2022;104:106767)".INTERNATIONAL JOURNAL OF SURGERY 106.(2022)